Application and Use of Transformative Emerging Technologies in Cancer Research (R33)

The summary for the Application and Use of Transformative Emerging Technologies in Cancer Research (R33) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Application and Use of Transformative Emerging Technologies in Cancer Research (R33)
	CFDA Number:	93.392
	CFDA Description:	Cancer Construction
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Education Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	RFA-CA-09-007
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Dec 15, 2008
	Creation Date:	Dec 15, 2008
	Original Closing Date for Applications:	Sep 30, 2009
	Current Closing Date for Applications:	Sep 30, 2009
	Archive Date:	Oct 31, 2009
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	$1,000,000
	Federal Grant Award Ceiling:	Information not provided
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments - Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Non-domestic (non-U.S.) Entities (Foreign Organizations); U.S. Territory or Possession.
Grant Description: Purpose. This Funding Opportunity Announcement (FOA) issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits grant applications proposing exceptionally innovative, high risk, original and/or unconventional research projects focused on evaluating the performance of emerging, potentially transformative molecular and cellular analysis technologies within the context of an appropriate cancer-relevant biological system. The emphasis of this FOA is on the application of emerging molecular and cellular analysis tools with the potential to (i) create new or challenge existing scientific and technological paradigms and/or (ii) overcome technological barriers in important areas of cancer research. Projects must clearly demonstrate potential to produce a major impact in a broad area of biomedical or cancer-relevant research through application to a relevant biological system. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. Several IMAT FOAs of identical or closely related scientific scope using various funding mechanisms are available. To facilitate selection, a separate Notice in the NIH Guide for Grants and Contracts provides brief cross-comparison and links to all the IMAT FOAs. See NOT-CA-09-007.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/rfa-ca-09-007.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Epigenetic Approaches in Cancer Epidemiology (R01); • Innovative and Applied Emerging Technologies in Biospecimen Science (R33); • Innovative and Applied Emerging Technologies in Biospecimen Science (R21); • Innovative Technology Development for Cancer Research (R21); • Application and Use of Transformative Emerging Technologies in Cancer Research (R21); • Small Grants Program for Cancer Epidemiology (R03)